SlideShare a Scribd company logo
1 of 79
Quantitative three-dimensional proton magnetic resonance spectroscopy in Multiple Sclerosis and Traumatic Brain Injury Ivan Kirov Advisor: Oded Gonen Department of Physiology and Neuroscience Sackler Institute of Biomedical Sciences, New York University
Presentation outline ,[object Object],[object Object],[object Object],[object Object]
Magnetic Resonance Imaging (MRI) ,[object Object],[object Object],[object Object],[object Object]
MR techniques ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conventional  MRI Anatomy Metabolism vs.  1 H-MRS
Cell classes and metabolite distribution in the brain
Motivation for MRS ,[object Object],[object Object]
MRS methods Single voxel  Multivoxel  Whole-brain Pros: Cons: Availability Simplicity Real-time results  Spatial resolution  (4 – 20 cc) Spatial coverage  (0.4 – 2% of brain) Spatial resolution (0.75 – 4 cc) Spatial coverage  (10 – 30% of brain) Metabolic maps Lengthy post-processing “ Voxel bleed” Samples entire brain  Short acquisition No misregistration errors in serial scans  No localization Only NAA is quantified 3D hybrid of 1D Hadamard with 2D chemical shift imaging Gonen  et al. , MRM 1997, MRM 1998
Data interpretation Qualitative Pixel values have numeric meaning  only in relation to neighboring pixels from the same dataset Information is derived from differences in contrast and is visually interpreted  Quantitative Values are converted to  absolute concentrations (Preferred) comparison is  to values in controls conventional MRI  vs.  MRS
MRS Quantification parameters ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Presentation outline ,[object Object],[object Object],[object Object],[object Object]
[object Object],Aim 1  Hypothesis
Introduction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Introduction Differences in  T 2   need to be taken into account to avoid interpreting them as concentration differences
Methods T 2  calculation 1  Fleysher,  et al . MRM   2007 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Methods  3D  1 H-MRS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Age dependence of regional proton metabolite  T 2 s in normal brain 1 1 Kirov  et al . MRM 2008 Metabolite  T 2 s in aging ,[object Object],[object Object],[object Object],[object Object],[object Object],Subjects
MRI/MRS – Adolescent WM ROIs: (a) Corona radiata (b) Genu (c) Splenium (d) Posterior WM  Kirov  et al . MRM 2008 Metabolite  T 2 s in aging
MRI/MRS – Elderly Kirov  et al . MRM 2008 Metabolite  T 2 s in aging
Kirov  et al . MRM 2008 Metabolite  T 2 s in aging ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results: g lobal  T 2 s Histograms of  T 2 s from all 320 voxels for all adolescents and elderly subjects Kirov  et al . MRM 2008 Metabolite  T 2 s in aging
Kirov  et al . MRM 2008 Metabolite  T 2 s in aging Results:  regional  T 2 s
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Kirov  et al . MRM 2008 Metabolite  T 2 s in aging
Proton metabolite  T 2 s in RR MS lesions and normal-appearing tissue 1 1 Kirov  et al . Radiology 2010 Metabolite  T 2 s in RR MS Subjects
MRI/MRS – RR MS patient 21F Disease duration: 2.6 yrs. EDSS: 1.5 VOI lesion volume: 23 cc Kirov  et al . Radiology 2010 Metabolite  T 2 s in RR MS
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ROIs: normal-appearing tissue Kirov  et al . Radiology 2010 Metabolite  T 2 s in RR MS
ROIs: lesions a   isointense b  hypointense Kirov  et al . Radiology 2010 Metabolite  T 2 s in RR MS
Results:  global  T 2 s Kirov  et al . Radiology 2010 Metabolite  T 2 s in RR MS Histograms of  T 2 s from all 320 voxels for all 10 patients
Results : regional  T 2 s Kirov  et al . Radiology 2010 Metabolite  T 2 s in RR MS
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Kirov  et al . Radiology 2010 Metabolite  T 2 s in RR MS
[object Object],Aim 1  Hypothesis
Presentation outline ,[object Object],[object Object],[object Object],[object Object]
[object Object],Aim 2  Hypothesis
[object Object],[object Object],[object Object],[object Object],[object Object],Multiple Sclerosis
Pathogenesis in the MS plaque Adapted from Frohman  et al ., NEJM 2006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Histological findings ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Type Focal (plaques) Diffuse Autopsy  and  biopsy
[object Object],Radiological findings ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],Quantitative MRI Magnetization transfer imaging Diffusion tensor imaging T 1  and T 2  relaxation time mapping MR Spectroscopy Radiological findings
MR Spectroscopy indicates diffuse Multiple Sclerosis activity during remission 1 1 Kirov  et al . JNNP 2009 Diffuse disease activity in MS Subjects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Methods: 3D  1 H-MRS PRESS with water suppression: VOI = 8 LR ×10 AP ×4.5 IS  = 360 cm 3   TE/TR  = 35/1800 ms, N=2 6 slices, FOV=16 AP ×16 LR  cm 2   Voxel number: 480 Voxel size 1.0 AP ×1.0 LR ×0.75 IS  = 0.75 cm 3 Kirov  et al . JNNP 2009 Diffuse disease activity in MS
[object Object],[object Object],[object Object],[object Object],[object Object],Methods: post-processing approach Kirov  et al . JNNP 2009 Diffuse disease activity in MS
Single voxel  vs.  summation Kirov  et al . JNNP 2009 Diffuse disease activity in MS
Methods : post-processing (contd.) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Kirov  et al . JNNP 2009 Diffuse disease activity in MS
[object Object],[object Object],Tissue fraction (T f ) = tissue volume/VOI volume Low T f  = High atrophy MIDAS segmentation package: De Santi, 2001 Methods : segmentation Kirov  et al . JNNP 2009 Diffuse disease activity in MS
MRI/MRS – RR MS patient 42F Disease duration: 2.1 yrs. EDSS: 0 VOI lesion volume: 4.2 cc Kirov  et al . JNNP 2009 Diffuse disease activity in MS
Summed spectra Each spectrum: –  is the sum of all voxels  in the VOI –  represents one subject –  gray line represents the  FITT function Results Kirov  et al . JNNP 2009 Diffuse disease activity in MS
Results a Years,  b inside the VOI, in cm 3 ,  c tissue fraction,  d p ‹0.01. *EDSS dominated by permanent visual impairment in one eye.   Kirov  et al . JNNP 2009 Diffuse disease activity in MS
metabolic concentrations tissue  fraction Results Kirov  et al . JNNP 2009 Diffuse disease activity in MS
Metabolites as disease markers Localization Suspected pathology  Finding  mI   ↑   Cr ↑  Cho ↑   –  astrogliosis  de/re-myelination Results Kirov  et al . JNNP 2009 Diffuse disease activity in MS
Since NAA loss and atrophy are observed in advanced disease these processes may precede (cause?) axonal damage ,[object Object],[object Object],[object Object],[object Object],[object Object],Conclusion Kirov  et al . JNNP 2009 Diffuse disease activity in MS
Presentation outline ,[object Object],[object Object],[object Object],[object Object]
[object Object],Aim 3  Hypothesis
Traumatic Brain Injury (TBI) ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],Mild  Traumatic Brain Injury (mTBI)
[object Object],[object Object],Need a reliable  biomarker   for mTBI Motivation for study
[object Object],[object Object],[object Object],[object Object],[object Object],1 H-MRS  – can detect occult damage by measuring [NAA], [Cr], [Cho] Neuronal injury Wallerian/retrograde  degeneration 1 Behrens,  Nature Neuroscience  2003 1 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Motivation for study
Characterizing mild TBI with proton MR spectroscopy in the thalamus 1 Subjects Controls:  17 age- and gender-matched Patients: 1 Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
Methods: 3D  1 H-MRS PRESS with water suppression: VOI = 8 LR ×10 AP ×6 IS  = 480 cm 3   TE/TR  = 135/1600 ms, N=2 8 slices, FOV=16 AP ×16 LR  cm 2   Voxel number: 640 Voxel size: 1.0 AP ×1.0 LR ×0.75 IS  = 0.75 cm 3 Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI MRI/MRS – mTBI patient
Methods:  post-processing Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
Methods:  post-processing Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
Thalamic metabolic concentrations Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI Results
Minimal detectable differences:  the minimal differences between patients and controls that would  produce significance ( p  < 0.05) Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI Results
[object Object],[object Object],[object Object],[object Object],Kirov  et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI Conclusion Metabolite Controls Patients Detectable Difference [NAA] 10.08 ± 0.3 9.60 ± 0.34 +/- 13.0% [Cr] 5.62 ± 0.18 5.44 ± 0.19 +/- 13.5% [Cho] 2.08 ± 0.09 2.03 ± 0.10 +/- 18.8%
List of publications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Acknowledgements Nissa Perry Joseph Reaume  Daniel Rigotti Henry Rusinek Jonathan Silver William Wu Wafaa Zaaraoui Ke Zhang
Supplemental slides - MS
Adapted from Hauser  et al ., Neuron 2006 Natural history
Possible causes of astrogliosis ,[object Object],[object Object],[object Object]
Implications Model of temporal evolution of pathogenesis in NAWM Diffuse disease activity in MS
Supplemental slides – acute mTBI
Subjects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Methods
Results ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Supplemental slides - miscellaneous
T 1 -weighting bias in  T 2  measurement with DSE
Detectable Differences ? = 8.8 mM or a 13% difference from the healthy controls’ mean
MRS Methodology ,[object Object],1 Gonen, MRM 1997, MRM 1998
[object Object],[object Object],[object Object],[object Object],Aging and the brain Subjects  Age  Brain changes with age 28 51 74 13 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],1 Jara,  Top Magn Reson Imaging , 2006  Brain iron and aging  1

More Related Content

What's hot

Ovarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_Elwell
Ovarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_ElwellOvarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_Elwell
Ovarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_ElwellZachary WareJoncas
 
Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...
Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...
Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...Professor Yasser Metwally
 
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...CrimsonpublishersCancer
 
To use or not to use the LQ model at “high” radiation doses
To use or not to use the LQ model at “high” radiation doses To use or not to use the LQ model at “high” radiation doses
To use or not to use the LQ model at “high” radiation doses Santam Chakraborty
 
Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...
Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...
Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...Thermo Fisher Scientific
 
Success and failures of combined modalities in GBM
Success and failures of combined modalities in GBMSuccess and failures of combined modalities in GBM
Success and failures of combined modalities in GBMapollo seminar group
 
Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...
Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...
Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...Ashley Kennedy
 
TH_publications
TH_publicationsTH_publications
TH_publicationsTord Hjalt
 
CV NOV 2014 Kazuyoshi KOHU
CV NOV 2014 Kazuyoshi KOHUCV NOV 2014 Kazuyoshi KOHU
CV NOV 2014 Kazuyoshi KOHUKazuyoshi Kohu
 
Role of EGFR in lung cancer:Resistance and Treatment
Role of EGFR in lung cancer:Resistance and TreatmentRole of EGFR in lung cancer:Resistance and Treatment
Role of EGFR in lung cancer:Resistance and TreatmentGirisha Maheshwari
 
Nsclc slide deck
Nsclc slide deckNsclc slide deck
Nsclc slide deckPLMMedical
 
Managing Health and Disease Using Omics and Big Data
Managing Health and Disease Using Omics and Big DataManaging Health and Disease Using Omics and Big Data
Managing Health and Disease Using Omics and Big DataLaura Berry
 
Targeting of TK1 to tumors for BNCT
Targeting of TK1 to tumors for BNCTTargeting of TK1 to tumors for BNCT
Targeting of TK1 to tumors for BNCTkent.riley
 
Thesis defense - QUANG ONG - FINAL
Thesis defense - QUANG ONG - FINALThesis defense - QUANG ONG - FINAL
Thesis defense - QUANG ONG - FINALQuang Ong
 
The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...
The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...
The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...Alexander Smith
 
List_of_publications_Dirk_Mueller
List_of_publications_Dirk_MuellerList_of_publications_Dirk_Mueller
List_of_publications_Dirk_Muellerdirkmuller8
 
Dissertation (rev 2011-05-23)_final_pdf
Dissertation (rev 2011-05-23)_final_pdfDissertation (rev 2011-05-23)_final_pdf
Dissertation (rev 2011-05-23)_final_pdfWalter Babiec
 

What's hot (19)

Ovarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_Elwell
Ovarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_ElwellOvarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_Elwell
Ovarian_Cancer_Presentation-Tritz_VanLith_WareJoncas_Elwell
 
Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...
Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...
Thesis section: The role of neuroimaging in muscle and peripheral nerve disor...
 
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...
 
To use or not to use the LQ model at “high” radiation doses
To use or not to use the LQ model at “high” radiation doses To use or not to use the LQ model at “high” radiation doses
To use or not to use the LQ model at “high” radiation doses
 
Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...
Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...
Assessment of TP53 Mutation Status in Breast Tumor Tissue using the "Ion Ampl...
 
Success and failures of combined modalities in GBM
Success and failures of combined modalities in GBMSuccess and failures of combined modalities in GBM
Success and failures of combined modalities in GBM
 
First-line Treatment In In EGFR Mutant NSCLC
First-line Treatment In In EGFR Mutant NSCLCFirst-line Treatment In In EGFR Mutant NSCLC
First-line Treatment In In EGFR Mutant NSCLC
 
Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...
Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...
Effects of Inflammatory Cytokines on Fibrosis-Related Gene Expression in Fibr...
 
TH_publications
TH_publicationsTH_publications
TH_publications
 
CV NOV 2014 Kazuyoshi KOHU
CV NOV 2014 Kazuyoshi KOHUCV NOV 2014 Kazuyoshi KOHU
CV NOV 2014 Kazuyoshi KOHU
 
Role of EGFR in lung cancer:Resistance and Treatment
Role of EGFR in lung cancer:Resistance and TreatmentRole of EGFR in lung cancer:Resistance and Treatment
Role of EGFR in lung cancer:Resistance and Treatment
 
Nsclc slide deck
Nsclc slide deckNsclc slide deck
Nsclc slide deck
 
Managing Health and Disease Using Omics and Big Data
Managing Health and Disease Using Omics and Big DataManaging Health and Disease Using Omics and Big Data
Managing Health and Disease Using Omics and Big Data
 
Targeting of TK1 to tumors for BNCT
Targeting of TK1 to tumors for BNCTTargeting of TK1 to tumors for BNCT
Targeting of TK1 to tumors for BNCT
 
Thesis defense - QUANG ONG - FINAL
Thesis defense - QUANG ONG - FINALThesis defense - QUANG ONG - FINAL
Thesis defense - QUANG ONG - FINAL
 
Benvenuti-Amigo.full
Benvenuti-Amigo.fullBenvenuti-Amigo.full
Benvenuti-Amigo.full
 
The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...
The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...
The Convergence of Endothelin and Androgen Signaling in the Metastasis of Pro...
 
List_of_publications_Dirk_Mueller
List_of_publications_Dirk_MuellerList_of_publications_Dirk_Mueller
List_of_publications_Dirk_Mueller
 
Dissertation (rev 2011-05-23)_final_pdf
Dissertation (rev 2011-05-23)_final_pdfDissertation (rev 2011-05-23)_final_pdf
Dissertation (rev 2011-05-23)_final_pdf
 

Similar to Thesis Defence

Magnetic resonance spectroscopy
Magnetic resonance spectroscopyMagnetic resonance spectroscopy
Magnetic resonance spectroscopyAnurag Singh
 
Basic physics and normal interpretation of MRS
Basic physics and normal interpretation of MRSBasic physics and normal interpretation of MRS
Basic physics and normal interpretation of MRStanzilur rahman
 
S0733861910001647
S0733861910001647S0733861910001647
S0733861910001647kingsofke
 
Presentation1, new mri techniques in the diagnosis and monitoring of multiple...
Presentation1, new mri techniques in the diagnosis and monitoring of multiple...Presentation1, new mri techniques in the diagnosis and monitoring of multiple...
Presentation1, new mri techniques in the diagnosis and monitoring of multiple...Abdellah Nazeer
 
Imrt A New Treatment Method For Nasopharyngeal Cancer
Imrt   A New Treatment Method For Nasopharyngeal CancerImrt   A New Treatment Method For Nasopharyngeal Cancer
Imrt A New Treatment Method For Nasopharyngeal Cancerfondas vakalis
 
Advances in neuro-imaging
Advances in neuro-imaging Advances in neuro-imaging
Advances in neuro-imaging Osama Ragab
 
Detecting the basis of cognitive dysfunction in mild Traumatic Brain Injury
Detecting the basis of cognitive dysfunction in mild Traumatic Brain InjuryDetecting the basis of cognitive dysfunction in mild Traumatic Brain Injury
Detecting the basis of cognitive dysfunction in mild Traumatic Brain InjuryYasir Hameed
 
Ben Turner - MRI workshop
Ben Turner -  MRI workshopBen Turner -  MRI workshop
Ben Turner - MRI workshopMS Trust
 
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...European School of Oncology
 
A typical Realization of the process with linear recovery of Aldosterone
A typical Realization of the process with linear recovery of AldosteroneA typical Realization of the process with linear recovery of Aldosterone
A typical Realization of the process with linear recovery of AldosteroneIJERA Editor
 
ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...
ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...
ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...ijistjournal
 
Can brain atrophy measurement help us in monitoring MS progression in routine...
Can brain atrophy measurement help us in monitoring MS progression in routine...Can brain atrophy measurement help us in monitoring MS progression in routine...
Can brain atrophy measurement help us in monitoring MS progression in routine...MS Trust
 
Multimodal MRI statistical segmentation of normal appearing white matter lesi...
Multimodal MRI statistical segmentation of normal appearing white matter lesi...Multimodal MRI statistical segmentation of normal appearing white matter lesi...
Multimodal MRI statistical segmentation of normal appearing white matter lesi...Antonio Carlos da Silva Senra Filho
 

Similar to Thesis Defence (20)

Magnetic resonance spectroscopy
Magnetic resonance spectroscopyMagnetic resonance spectroscopy
Magnetic resonance spectroscopy
 
Basic physics and normal interpretation of MRS
Basic physics and normal interpretation of MRSBasic physics and normal interpretation of MRS
Basic physics and normal interpretation of MRS
 
S0733861910001647
S0733861910001647S0733861910001647
S0733861910001647
 
Presentation1, new mri techniques in the diagnosis and monitoring of multiple...
Presentation1, new mri techniques in the diagnosis and monitoring of multiple...Presentation1, new mri techniques in the diagnosis and monitoring of multiple...
Presentation1, new mri techniques in the diagnosis and monitoring of multiple...
 
Imrt A New Treatment Method For Nasopharyngeal Cancer
Imrt   A New Treatment Method For Nasopharyngeal CancerImrt   A New Treatment Method For Nasopharyngeal Cancer
Imrt A New Treatment Method For Nasopharyngeal Cancer
 
MRS
MRS MRS
MRS
 
Dr. Romaguera MCL
Dr. Romaguera MCLDr. Romaguera MCL
Dr. Romaguera MCL
 
MRS.pptx
MRS.pptxMRS.pptx
MRS.pptx
 
Mehta.ppt
Mehta.pptMehta.ppt
Mehta.ppt
 
Scientifi c Journal of Multiple Sclerosis
Scientifi c Journal of Multiple SclerosisScientifi c Journal of Multiple Sclerosis
Scientifi c Journal of Multiple Sclerosis
 
Advances in neuro-imaging
Advances in neuro-imaging Advances in neuro-imaging
Advances in neuro-imaging
 
Detecting the basis of cognitive dysfunction in mild Traumatic Brain Injury
Detecting the basis of cognitive dysfunction in mild Traumatic Brain InjuryDetecting the basis of cognitive dysfunction in mild Traumatic Brain Injury
Detecting the basis of cognitive dysfunction in mild Traumatic Brain Injury
 
Ben Turner - MRI workshop
Ben Turner -  MRI workshopBen Turner -  MRI workshop
Ben Turner - MRI workshop
 
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
 
A typical Realization of the process with linear recovery of Aldosterone
A typical Realization of the process with linear recovery of AldosteroneA typical Realization of the process with linear recovery of Aldosterone
A typical Realization of the process with linear recovery of Aldosterone
 
ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...
ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...
ANALYTICAL STUDY OF BRAIN MRI PROTOCOLS, SEQUENCES AND PARAMETERS FOR DETECTI...
 
The State of Scleroderma Clinical Trials
The State of Scleroderma Clinical TrialsThe State of Scleroderma Clinical Trials
The State of Scleroderma Clinical Trials
 
HNSS Poster Draft v6
HNSS Poster Draft v6HNSS Poster Draft v6
HNSS Poster Draft v6
 
Can brain atrophy measurement help us in monitoring MS progression in routine...
Can brain atrophy measurement help us in monitoring MS progression in routine...Can brain atrophy measurement help us in monitoring MS progression in routine...
Can brain atrophy measurement help us in monitoring MS progression in routine...
 
Multimodal MRI statistical segmentation of normal appearing white matter lesi...
Multimodal MRI statistical segmentation of normal appearing white matter lesi...Multimodal MRI statistical segmentation of normal appearing white matter lesi...
Multimodal MRI statistical segmentation of normal appearing white matter lesi...
 

Thesis Defence

  • 1. Quantitative three-dimensional proton magnetic resonance spectroscopy in Multiple Sclerosis and Traumatic Brain Injury Ivan Kirov Advisor: Oded Gonen Department of Physiology and Neuroscience Sackler Institute of Biomedical Sciences, New York University
  • 2.
  • 3.
  • 4.
  • 5. Conventional MRI Anatomy Metabolism vs. 1 H-MRS
  • 6. Cell classes and metabolite distribution in the brain
  • 7.
  • 8. MRS methods Single voxel Multivoxel Whole-brain Pros: Cons: Availability Simplicity Real-time results Spatial resolution (4 – 20 cc) Spatial coverage (0.4 – 2% of brain) Spatial resolution (0.75 – 4 cc) Spatial coverage (10 – 30% of brain) Metabolic maps Lengthy post-processing “ Voxel bleed” Samples entire brain Short acquisition No misregistration errors in serial scans No localization Only NAA is quantified 3D hybrid of 1D Hadamard with 2D chemical shift imaging Gonen et al. , MRM 1997, MRM 1998
  • 9. Data interpretation Qualitative Pixel values have numeric meaning only in relation to neighboring pixels from the same dataset Information is derived from differences in contrast and is visually interpreted Quantitative Values are converted to absolute concentrations (Preferred) comparison is to values in controls conventional MRI vs. MRS
  • 10.
  • 11.
  • 12.
  • 13.
  • 14. Introduction Differences in T 2 need to be taken into account to avoid interpreting them as concentration differences
  • 15.
  • 16.
  • 17.
  • 18. MRI/MRS – Adolescent WM ROIs: (a) Corona radiata (b) Genu (c) Splenium (d) Posterior WM Kirov et al . MRM 2008 Metabolite T 2 s in aging
  • 19. MRI/MRS – Elderly Kirov et al . MRM 2008 Metabolite T 2 s in aging
  • 20.
  • 21. Results: g lobal T 2 s Histograms of T 2 s from all 320 voxels for all adolescents and elderly subjects Kirov et al . MRM 2008 Metabolite T 2 s in aging
  • 22. Kirov et al . MRM 2008 Metabolite T 2 s in aging Results: regional T 2 s
  • 23.
  • 24. Proton metabolite T 2 s in RR MS lesions and normal-appearing tissue 1 1 Kirov et al . Radiology 2010 Metabolite T 2 s in RR MS Subjects
  • 25. MRI/MRS – RR MS patient 21F Disease duration: 2.6 yrs. EDSS: 1.5 VOI lesion volume: 23 cc Kirov et al . Radiology 2010 Metabolite T 2 s in RR MS
  • 26.
  • 27. ROIs: lesions a isointense b hypointense Kirov et al . Radiology 2010 Metabolite T 2 s in RR MS
  • 28. Results: global T 2 s Kirov et al . Radiology 2010 Metabolite T 2 s in RR MS Histograms of T 2 s from all 320 voxels for all 10 patients
  • 29. Results : regional T 2 s Kirov et al . Radiology 2010 Metabolite T 2 s in RR MS
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40. Methods: 3D 1 H-MRS PRESS with water suppression: VOI = 8 LR ×10 AP ×4.5 IS = 360 cm 3 TE/TR = 35/1800 ms, N=2 6 slices, FOV=16 AP ×16 LR cm 2 Voxel number: 480 Voxel size 1.0 AP ×1.0 LR ×0.75 IS = 0.75 cm 3 Kirov et al . JNNP 2009 Diffuse disease activity in MS
  • 41.
  • 42. Single voxel vs. summation Kirov et al . JNNP 2009 Diffuse disease activity in MS
  • 43.
  • 44.
  • 45. MRI/MRS – RR MS patient 42F Disease duration: 2.1 yrs. EDSS: 0 VOI lesion volume: 4.2 cc Kirov et al . JNNP 2009 Diffuse disease activity in MS
  • 46. Summed spectra Each spectrum: – is the sum of all voxels in the VOI – represents one subject – gray line represents the FITT function Results Kirov et al . JNNP 2009 Diffuse disease activity in MS
  • 47. Results a Years, b inside the VOI, in cm 3 , c tissue fraction, d p ‹0.01. *EDSS dominated by permanent visual impairment in one eye. Kirov et al . JNNP 2009 Diffuse disease activity in MS
  • 48. metabolic concentrations tissue fraction Results Kirov et al . JNNP 2009 Diffuse disease activity in MS
  • 49. Metabolites as disease markers Localization Suspected pathology Finding mI ↑ Cr ↑ Cho ↑ – astrogliosis de/re-myelination Results Kirov et al . JNNP 2009 Diffuse disease activity in MS
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56.
  • 57. Characterizing mild TBI with proton MR spectroscopy in the thalamus 1 Subjects Controls: 17 age- and gender-matched Patients: 1 Kirov et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
  • 58. Methods: 3D 1 H-MRS PRESS with water suppression: VOI = 8 LR ×10 AP ×6 IS = 480 cm 3 TE/TR = 135/1600 ms, N=2 8 slices, FOV=16 AP ×16 LR cm 2 Voxel number: 640 Voxel size: 1.0 AP ×1.0 LR ×0.75 IS = 0.75 cm 3 Kirov et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
  • 59. Kirov et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI MRI/MRS – mTBI patient
  • 60. Methods: post-processing Kirov et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
  • 61. Methods: post-processing Kirov et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI
  • 62. Thalamic metabolic concentrations Kirov et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI Results
  • 63. Minimal detectable differences: the minimal differences between patients and controls that would produce significance ( p < 0.05) Kirov et al . Brain Injury 2007 1 H-MRS of the thalamus in mTBI Results
  • 64.
  • 65.
  • 66.
  • 68. Adapted from Hauser et al ., Neuron 2006 Natural history
  • 69.
  • 70. Implications Model of temporal evolution of pathogenesis in NAWM Diffuse disease activity in MS
  • 72.
  • 74.
  • 75. Supplemental slides - miscellaneous
  • 76. T 1 -weighting bias in T 2 measurement with DSE
  • 77. Detectable Differences ? = 8.8 mM or a 13% difference from the healthy controls’ mean
  • 78.
  • 79.

Editor's Notes

  1. MRI has several clear advantages over other types of neuroimaging. It uses low frequency radiation in the radio wave spectrum. That is unlike CT which uses X-rays and PET and SPECT which use radioactive isotopes. Other non-ionizing techniques, such as EEG, MEG and near-infrared spec, can only image the cerebral cortex. MRI, on the other hand, can visualize the anatomy and assess various types of tissue function in the ENTIRE brain. EEG, magnetoencephalography MEG and near-infrared imaging NIRI
  2. By far, the most popular MR technique is the T1/T2 weighted MRI, known as conventional MRI. Beyond that, there is a plethora of other MR techniques which add sensitivity and specificity to different types of injury. The MR tool used in this dissertation is MR Spectroscopy or MRS.
  3. Conventional MRI image, in this case a T2-weighted FLAIR image, visualizes brain anatomy, whereas MRS gives information about metabolism from a defined brain region called a voxel. A proton MRS spectrum of the brain contains the peaks of four main metabolites: mI, Cho, Cr and NAA. The protons which contribute to the respective peaks are circled on this slide. The areas of each peak is proportional to the concentration of that metabolite. Conventional MRI, which provides anatomical images can be supplemented with MRS, which provides local metabolic information. MRS is the only non-invasive method for assessing human biochemistry in vivo As a clinical tool, it received approval of the FDA in 1995. Proton MRS (1H-MRS), in particular, is best suited for clinical applications since it uses the standard hardware of a MR scanner, and thus is readily incorporated in a routine MR protocol. In this way, localized MRS data adds specificity to structural MRI with information about local metabolism.
  4. Let’s talk briefly about cell classes and the distribution of those metabolites in the brain. The CNS has 2 classes of cells – neurons and glia. The neuron receives innervation via its dendrites and if that input is excitatory it generates an action potential which travels through the axon, innervating the dendrites of other neurons. The major types of glia are the astrocytes and oligodendrocytes. The astrocytes contact the neuronal cell body providing structural and functional support. They also line the capillaries and their end-feet form the blood brain barrier. Oligodendrocytes secrete a lipid-rich membrane, which envelopes the neuronal axon, enabling the propagation of the action potential. In MS, as you will see later, myelin breakdown due to inflammation results in impaired signal propagation and subsequent axonal damage, resulting in a variety of neurological deficits. Cr and Cho are present in all 3 cell types, but are most abundant in oligodendrocytes and least in neurons. mI is unique to astrocytes, and NAA is unique to neurons, rendering the two markers for the respective cell type.
  5. The motivation for MRS is that……. Therefore, … &gt;&gt;&gt;&gt; Presumably the beginning of a disease process is characterized by metabolic changes, which precede (or maybe even give rise to) changes in anatomy. Therefore, one of the potential uses of MRS is in earlier diagnosis.
  6. A word about Data intepretation in MRS. Unlike cMRI, which is qualitative, in MRS values are usually converted to absolute concentrations. And while…. &gt;&gt;&gt;&gt;&gt; To understand why T2 times are important, we have to discuss the nature of data interpretation in MRS. Unlike conventional MRI, MRS data is quantitative. In MRI the relationship between pixels is relative. Qualitative MRI data is not comparable to other MRI scans, or even to MRI scans of the same person scanned at a different time. &gt;&gt;&gt;
  7. We therefore need to account for many parameters that influence MRS quantification. Some parameters are set by the acquisition protocol. These are known and include TR, TE and voxel size. You have to take into account possible inhomogeneities in Bo and B1. And finally, you have to be aware that variations in the molecular environment can affect T1 and T2 relaxation times.
  8. A quick introduction on how T2 times are related to quantification. Only at the junction of the function and y-axis is the signal = concentration. Therefore we would need a TE=0 to measure true concentration. But TE cannot be equal to 0, so the signal is T2-weighted. Therefore T2s are needed to find spin density, but they are not obtained for every patient, and the use of one T2 has been assumed to be ok for all tissue types and all people. In order to be sure that we are measuring true concentrations of disease changes and not different T2 times, we need to address this issue.
  9. Here is a hypothetical example of how differences in T2 can bias results. Both patient and control have the same concentration of this metabolite, but different T2s. If we assume that patients’ T2 is the same as the controls’ we will infer that the patient has lower concentration of this metabolite
  10. Measuring T2 is done by taking several measurements at diff. TEs and since c (concentration) is always the same, the signal decay curve and T2 can be extrapolated. Usually only the TEs are changed, keeping all other acquisition parameters the same, including the number of averages. Our method does not put such restrictions and optimizes all parameters per unit time. It shows that the most efficient use of 4 measurements is to take data at only 2 TEs, with different number of averages at each one. At TE1, 1 average, at TE2, 3 averages. This makes sense because at the short TE the SNR is very high and we don’t need more than 1 average. At the long TE, however, we take 3 averages, because the SNR is much worse. By optimizing protocol most averaging is done at the long TE, instead of having the same number of averages at both short and long TE. The method defines the TEs the following way: Method says TE1=0 or as close as possible to 0. The sequence that we have cannot go under 35ms. Optimal TE2 is very long, but there is a great signal decay at long TEs. T2 guess – error of incorrect guess is very small in the range of 150- 250. bad SNR = need averaging.
  11. In the first study we looked at the “age dependence ….”.
  12. We measured the T2s in 5 WM and 5 GM structures. Four of the WM ROIs are shown in this figure. This also shows the placement of the MRS VOI in the brain of an adolescent volunteer. To the right are the spectra at both TEs, with the ones obtained at 260ms magnified 2.5 times. Compare this to this anatomical section in the elderly.
  13. The most dramatic difference of course is in the enlarged ventricles, result of normal brain atrophy that occurs with age. The rate that this happens is ¼%/year. Similar SNR , resolution, between adolescent and elderly.
  14. One histogram represents one person. Each histogram shows the T2s of all 320 voxels of all 4 slices per person. T2 values are on the x-axis, and their frequency is on the y-axis. The histogram width is a measure of the T2 variations in that individual. The fact that for each metabolite histogram widths are similar in all people, indicates no change in intra-individual T2 variations. The other take home message from this figure is that in terms of T2s, people are also similar to one another and that does not change with age. This is evidenced by the fact that all histograms are overlapping. There are 2 take home messages from this figure. The T2 variations within individuals are similar in all people, of all age groups. the 2 age-extreme cohorts we can assess any age effects on the T2s: 1. No significant change in the mean T2s. 2. No change in the intra -subject distribution – the width of the histograms for adolescents and elderly are very similar. 3. No marked difference b/n individuals – the histograms at about age groups are stacked together in a similar fashion. Because we know the lower limit of the instrumental contribution to the CV we can estimate that almost all of the histograms width is due to biological variation.
  15. This is a plot of age versus T2 separated by tissue type. Differences between GM and WM: 30% for NAA, 16% for Cr, and 10% for Cho. (most likely due to diffusion – in WM there is only perpendicular diffusion so relaxation rate is slower). It is not due to iron because the rates of T2 decline are the same for both WM and GM and there is more iron deposition in GM. Iron probably exerts a mesoscopic effect which is not seen here. The differences between T2s of either WM or GM in the adolescents and the elderly are: 12% for NAA, 6% for Cr, and 9% for Cho. It is likely that the observed T2 therefore, is a result of only the true T2 and diffusion effects. These age-corrections for the T2 s can improve the accuracy of absolute metabolic quantification by up to half the 12%, 6% and 9% differences of NAA, Cr and Cho between the young and elderly compared with the use of a single T2 per metabolite.
  16. At what TE is the quantification error produced by the range of T2s 10%? This range includes 1, 2 and 3. Of course at shorter TEs, the error becomes smaller. ----At what TE is the quantification error produced by neglecting the range of T2 s (between structures, individuals and age groups) less than 10%? We accept 10% as acceptable error. Then we ask at what TE can we neglect the range of T2s that we measure. Here are 2 t2s that are very different. Let them represent the largest diff. in t2s that we find. The 2 t2s may be of diff. structures, people, and age groups, but represent the largest difference between t2s. Other way to say question is: if the range of t2s is neglected (i.e. you use one or the other) what is the incurred quantification error for the TE that you are using. So even if there is sign. difference between T2s, what’s important is to what error in quantification this will lead.
  17. Emphasize the heterogeneity of the cohort.
  18. PRESS is 90-180-180 pulses
  19. 10 structures will be probed as well as both hypo- and iso-intense lesions
  20. intra -subject T2 variations = FWHH of the histograms
  21. The exact cause of MS is unknown. It is believed that an unknown antigen, perhaps a virus, triggers a T cell mediated auto-immune response. Activated lymphocytes digest the basement membrane of the blood-brain-barrier and enter the central nervous system. There they initiate a pro-inflammatory cascade which involves many cytokines including interferon-gamma and interleukin-17. This results in the accumulation of T, B cells, macrophages and microglia which destroy the myelin sheaths of axons. In the process, nitric oxide, oxygen free radicals and glutamate are released and these may damage the naked axons. Ca influx is also harmful. Continued attacks in the same location cause axonal transection and astrogliosis. Oligodendrocyte progenitors are recruited to the site of damage and some remyelination can take place, but it is usually incomplete.
  22. Autopsy and biopsy findings confirm all of these processes in MS plaques. There is other type of pathology, however, which is diffuse, or in other words, found throughout the rest of the brain. Findings there are less pronounced/dramatic and are not consistent across studies, but include ……… In advanced disease there are reports of inflammation and demyelination.
  23. What does the disease look like in-vivo on MRI? The gold standard in diagnosis and treatment monitoring of MS is T1 and T2-weighted MRI, due to their ability to detect the focal type of damage, manifesting as hyperintensities on this T2-weighted example. However, it is relatively non-specific to the occurring pathology inside the lesion and these lesions do not correlate well with clinical disability. T1 and T2-weighted MRI also lack sensitivity to detect the diffuse abnormalities and outside of the lesions tissue is normal-appearing.
  24. The pathology in in normal-appearing tissue, however, is detectable with quantitative MR methods such as MRS. These methods have found abnormalities in all disease stages, MS subgroups, and some have been found to correlate with disability and lesion evolution.
  25. In our study we used MRS and found diffuse abnormalities studying 21 recently diagnosed, mildly disabled, patients, during remission. 15-age and gender matched controls were also recruited.
  26. The 360 cc VOI is composed of mostly WM, so our post-processing approach was to sum all 480 voxels in order to obtain a single spectrum indicative of diffuse processes throughout the WM.
  27. On this slide we compare our approach to a single voxel experiment. While SNRs are comparable, the spectral resolution of the summation approach is far superior. This exploits the fact that the B0 homogeneity is better across small voxels, and the narrow linewidths are preserved in the sum. To achieve this the spectra need to be aligned the spectra before the summation. &gt;&gt;&gt;&gt; 1. better B0 homogeneity across small voxels. 2. better SNR by the square root of the number of voxels, because averaging all voxels mimics increasing the number of acquisitions that many times.
  28. The whole post-processing method is presented here.
  29. Absolute amounts were converted in concentrations by dividing by the tissue fraction inside the VOI. The tissue fraction is also a measure of atrophy inside the VOI, with low values corresponding to high atrophy.
  30. Here only the results from the patients are shown. Average lesion volume inside the VOI was 2%, there was no atrophy or NAA loss. In contrast there were significant elevations in Cr, Cho and mI.
  31. Box plots of these values reveal 9% increase for Cr, 14% for Cho and 20% for mI. Note that there was no statistical difference in the NAA or tissue fraction.
  32. To interpret these findings we again look at the metabolite localization within the various CNS cell types. The size of the font is proportional to the amount of that metabolite in one cell type in respect to the others. NAA is unique to neurons and mI is only found in astrocytes. Therefore, our findings, we interpret as astrogliosis and de/remyelination.
  33. Connectivity maps are gotten using diffusion imaging using a tractography algorhythm. “ connectivity based GM segmentation”.
  34. Months from TBI: 2 months to 7 years
  35. Peak areas were estimated by an automated fitting software (FITT)1, which uses acquisition specific information. Quantification errors due to the use of one T2 value per metabolite in the thalamus: NAA: 3.5 % Cr: 6.7 % Cho: 7.2 % Relative concentrations were converted to absolute by calculating a conversion factor that normalized the mean of each metabolite in the controls to its literature value and then applying it to patients and controls.
  36. - We would need to recruit more than 60 patients to see significance at the 5% level. - The min. detectable differences define the sensitivity of our measurement. - They are the smallest metabolite concentration changes which would produce significant differences between patients and controls - To see significance, we can either improve the sensitivity of the technique or increase cohorts
  37. ---If the mean of the patient distribution were outside of these ranges, we would have seen a significant difference. Since we did not, then the changes caused by mTBI are within that range. Can we define the limits of thalamic metabolic change imparted by mTBI? Yes, that is the same as defining the sensitivity of our technique. E.g.: The change in NAA must be between +/-13% with respect to the controls, otherwise we would have seen significant difference
  38. At the long TE, magnetization has more time to recover between the pulses, but less at the end resulting in a different steady state. This results in a factor that does not cancel out in the equation for T2 calculation. This may result in an underestimation of T2s by as much as 30%. This can be overcome by a long TR or saturating the longitudinal magnetization and providing the same recovery time at all TEs. 20% uncertainty in T1 values leads to less thatn 3% bias in T2s.
  39. Can we define the limits of thalamic metabolic change imparted by mTBI? Yes, that is the same as defining the sensitivity of our technique. E.g.: The change in NAA must be between +/-13% with respect to the controls, otherwise we would have seen significant difference